Carotid and Renal Artery Stents Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report Download FREE Resources

Published: November 08, 2024 Report Code: GDME1880EPD-ST

Select Item

Carotid and Renal Artery Stents Pipeline Market Report Overview

Carotid artery stents are expandable tubes that are implanted in narrowed carotid arteries to increase the flow of blood. Carotid arteries become narrowed due to plaque formation and buildup in the inner surface of the arteries. Carotid stenosis is further divided into two indications: symptomatic and asymptomatic carotid stenosis. Patients with symptomatic carotid stenosis can present with symptoms such as transient ischemic attacks or temporary vision loss.

Carotid and renal artery stents pipeline report provides data related to the major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths, and estimated approval dates. The report also provides reviews of major players involved in the pipeline product development.

Key Territories ·       The United States

·       China

·       Europe

·       Taiwan

·       Israel
Key Categories ·       Carotid Artery Bare Metal Stents

·       Renal Artery Bare Metal Stents
Key Regulatory Paths ·       NMPA

·       PMA

·       CE

·       HSA

·       MDL
Leading Companies ·       Acotec Scientific Holdings Ltd

·       CR Bard Inc

·       Evasc Medical Systems Corp

·       InspireMD Inc

·       Loyola University Chicago
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Carotid and Renal Artery Stents Pipeline Market Segmentation by Categories

The key categories in the Carotid and Renal Artery Stents pipeline market are carotid artery bare metal stents and renal artery bare metal stents. As of November 2024, carotid artery bare metal stents have the highest number of pipeline products.

Carotid and Renal Artery Stents Pipeline Market Analysis by Categories, 2024 (%)

Carotid and Renal Artery Stents Pipeline Market Analysis by Categories, 2024 (%)

Buy the Full Report for More Category Insights into the Carotid and Renal Artery Stents Pipeline Market

Download a Free Report Sample

Carotid and Renal Artery Stents Pipeline Market Segmentation by Territories

A few of the key territories associated with the carotid and renal artery stents pipeline market are the United States, China, Europe, Taiwan, and Israel among others. As of November 2024, the US and China have the highest number of carotid and renal artery stents pipeline products.

Carotid and Renal Artery Stents Pipeline Market Analysis by Territories, 2024 (%)

Carotid and Renal Artery Stents Pipeline Market Analysis by Territories, 2024 (%)

Buy the Full Report for More Territory Insights into the Carotid and Renal Artery Stents Pipeline Market

Download a Free Report Sample

Carotid and Renal Artery Stents Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths in the carotid and renal artery stents pipeline products market are NMPA, PMA, CE, HAS, and MDL. As of November 2024, NMPA and PMA are the most followed pathways for pipeline products in the carotid and renal artery stents market.

Carotid and Renal Artery Stents Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Carotid and Renal Artery Stents Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Buy the Full Report for More Regulatory Path Insights into the Carotid and Renal Artery Stents Pipeline Market

Download a Free Report Sample

Carotid and Renal Artery Stents Pipeline Market – Competitive Landscape

A few of the key companies associated with the carotid and renal artery stents pipeline market are Acotec Scientific Holdings Ltd, CR Bard Inc, Evasc Medical Systems Corp, InspireMD Inc, and Loyola University Chicago among others.

Acotec Scientific Holdings Ltd: Acotec Scientific Holdings Ltd, a subsidiary of Boston Scientific Corp, is a medical technology company that specializes in the research, development, and application of technology platforms in the field of vascular interventional treatment. It offers four technology platforms: drug coating technology, radiofrequency ablation technology, polymer material technology, and suction platform technology.

CR Bard Inc: CR Bard Inc, a subsidiary of Becton Dickinson and Co, develops and markets medical devices that include foley catheters, trays, collection systems, and intermittent catheters.

Carotid and Renal Artery Stents Pipeline Market Analysis by Companies, As of November 2024
Carotid and Renal Artery Stents Pipeline Market Analysis by Companies, As of November 2024Buy the Full Report for More Company Insights into the Carotid and Renal Artery Stents Pipeline Market
Download a Free Report Sample

Segments Covered in the Report

Carotid and Renal Artery Stents Pipeline Market Territories Outlook (2024)

  • The United States
  • China
  • Europe
  • Taiwan
  • Israel

Carotid and Renal Artery Stents Pipeline Market Regulatory Paths Outlook (2024)

  • NMPA
  • PMA
  • CE
  • HAS
  • MDL

Carotid and Renal Artery Stents Pipeline Market Categories Outlook (2024)

  • Carotid Artery Bare Metal Stents
  • Renal Artery Bare Metal Stents

Scope

This report provides:

  • Extensive coverage of the carotid and renal artery stents under development.

  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details, and other developmental activities.

  • The report reviews the major players involved in the development of carotid and renal artery stents and lists all their pipeline projects.

  • The coverage of pipeline products is based on various stages of development ranging from early development to approved/issued stage.

  • The report provides key clinical trial data of ongoing trials specific to pipeline products.

  • Recent developments in the segment/industry.

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.

  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain competitive advantage.

  • Identify and understand important and diverse types of Carotid and Renal Artery Stents under development.

  • Develop market-entry and market-expansion strategies.

  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.

  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Acotec Scientific Holdings Ltd
CR Bard Inc
Evasc Medical Systems Corp
InspireMD Inc
Loyola University Chicago
MicroPort Scientific Corp
Nesstent Ltd.
Palmaz Scientific Inc (Inactive)
Shanghai HeartCare Medical Technology Co Ltd
SurModics Inc

Table of Contents

  • 1 Table of Contents

  • 1.1 List of Tables

  • 1.2 List of Figures

  • 2 Introduction

    • 2.1 Carotid and Renal Artery Stents Overview

  • 3 Products under Development

    • 3.1 Carotid and Renal Artery Stents – Pipeline Products by Stage of Development

    • 3.2 Carotid and Renal Artery Stents – Pipeline Products by Segment

    • 3.3 Carotid and Renal Artery Stents – Pipeline Products by Territory

    • 3.4 Carotid and Renal Artery Stents – Pipeline Products by Regulatory Path

    • 3.5 Carotid and Renal Artery Stents – Pipeline Products by Estimated Approval Date

    • 3.6 Carotid and Renal Artery Stents – Ongoing Clinical Trials

  • 4 Carotid and Renal Artery Stents – Pipeline Products under Development by Companies

    • 4.1 Carotid and Renal Artery Stents Companies – Pipeline Products by Stage of Development

    • 4.2 Carotid and Renal Artery Stents – Pipeline Products by Stage of Development

  • 5 Carotid and Renal Artery Stents Companies and Product Overview

    • 5.1 Acotec Scientific Holdings Ltd Company Overview

      • 5.1.1 Acotec Scientific Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.2 CR Bard Inc Company Overview

      • 5.2.1 CR Bard Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.3 Evasc Medical Systems Corp Company Overview

      • 5.3.1 Evasc Medical Systems Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.4 InspireMD Inc Company Overview

      • 5.4.1 InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.5 Loyola University Chicago Company Overview

      • 5.5.1 Loyola University Chicago Pipeline Products & Ongoing Clinical Trials Overview

    • 5.6 MicroPort Scientific Corp Company Overview

      • 5.6.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.7 Nesstent Ltd. Company Overview

      • 5.7.1 Nesstent Ltd. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.8 Palmaz Scientific Inc (Inactive) Company Overview

      • 5.8.1 Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview

    • 5.9 Shanghai HeartCare Medical Technology Co Ltd Company Overview

      • 5.9.1 Shanghai HeartCare Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.10 SurModics Inc Company Overview

      • 5.10.1 SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview

  • 6 Carotid and Renal Artery Stents- Recent Developments

    • 6.1 Oct 23, 2024: Boston Scientific Reports Results for Q3 2024

    • 6.2 Oct 21, 2024: Contego Medical Obtains Pre-market Approval (PMA) For Neuroguard IEP System

    • 6.3 Oct 21, 2024: Contego Medical obtains additional Pre-Market Approval (PMA) for Neuroguard IEP System

    • 6.4 Oct 15, 2024: Contego Medical’s Neuroguard IEP System Receives FDA Approval for Carotid Revascularization, New Standard in 30-day and 1 year Stroke Outcomes

    • 6.5 Oct 02, 2024: Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results

    • 6.6 Sep 16, 2024: InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard Prime Carotid Stent System

    • 6.7 Aug 30, 2024: MicroPort Scientific Reports Earnings Results for the Half Year Ended June 30, 2024

    • 6.8 Aug 27, 2024: Medtronic Chairman and CEO Geoff Martha to Speak at the Wells Fargo Healthcare Conference

    • 6.9 Aug 27, 2024: Medtronic Chairman and CEO Geoff Martha to Speak at the Wells Fargo Healthcare Conference

    • 6.10 Aug 05, 2024: InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

    • 6.11 Jul 30, 2024: Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures

    • 6.12 Jul 24, 2024: MicroPort NeuroTech Completes World’s First Application of PCAR Intervention System

    • 6.13 Jun 13, 2024: Medtronic Confirms Global Layoffs

    • 6.14 May 28, 2024: Inspiremd Announces Presentation Of Positive One-year Follow-up Results From The C-guardians U.S. Investigational Device Exemption (Ide) Clinical Trial Of Cguard At Linc 2024

    • 6.15 Mar 26, 2024: InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

    • 6.16 Mar 14, 2024: Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit

    • 6.17 Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference

    • 6.18 Mar 07, 2024: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China

    • 6.19 Mar 05, 2024: Silk Road Medical Expands TCAR Portfolio with Launch of Tapered ENROUTE Transcarotid Stent System

    • 6.20 Feb 28, 2024: InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update

    • 6.21 Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company

    • 6.22 Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering

    • 6.23 Jan 31, 2024: InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

    • 6.24 Jan 16, 2024: Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

    • 6.25 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results

    • 6.26 Nov 27, 2023: Inspiremd Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of Cguard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

  • 7 Appendix

    • 7.1 Methodology

    • 7.2 About GlobalData

    • 7.3 Contact Us

    • 7.4 Disclaimer

Table

Carotid and Renal Artery Stents – Pipeline Products by Stage of Development

Carotid and Renal Artery Stents – Pipeline Products by Segment

Carotid and Renal Artery Stents – Pipeline Products by Territory

Carotid and Renal Artery Stents – Pipeline Products by Regulatory Path

Carotid and Renal Artery Stents – Pipeline Products by Estimated Approval Date

Carotid and Renal Artery Stents – Ongoing Clinical Trials

Carotid and Renal Artery Stents Companies – Pipeline Products by Stage of Development

Carotid and Renal Artery Stents – Pipeline Products by Stage of Development

Acotec Scientific Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview

Carotid Stent – Product Status

Carotid Stent – Product Description

CR Bard Inc Pipeline Products & Ongoing Clinical Trials Overview

VIVEXX Carotid Stent – Product Status

VIVEXX Carotid Stent – Product Description

Evasc Medical Systems Corp Pipeline Products & Ongoing Clinical Trials Overview

ROSS – Renal Ostial Stent System – Product Status

ROSS – Renal Ostial Stent System – Product Description

InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview

CGuard Embolic Prevention System – Product Status

CGuard Embolic Prevention System – Product Description

Next Gen CGuard – 5F – Product Status

Next Gen CGuard – 5F – Product Description

RGuard Renal – Product Status

RGuard Renal – Product Description

InspireMD Inc – Ongoing Clinical Trials Overview

CGuard Embolic Prevention System – Acute Stroke of Carotid Artery Bifurcation Origin Treated with Use of the Micronet-covered CGUARD Stent Under Transient Flow Reversal Linked with Thrombus Retrieval: SAFEGUARD-STROKE Study

CGuard Embolic Prevention System – An Early Feasibility Study (EFS) Assessing the CGuard Embolic Prevention Carotid Stent to Treat Severe Carotid Stenosis or Occlusion

CGuard Embolic Prevention System – Long-term Outcomes of MicroNet-covered Stent Routine Use for Stroke Prevention in Symptomatic and Increased-risk Asymptomatic Carotid Stenosis Patients Requiring Revascularization by Neurovascular Team Decision: PARADIGM-EXTEND

CGuard Embolic Prevention System – OPTIMAl Endovascular Exclusion of High-risk Carotid Plaque Using the CGuard Stent in Patients with Symptoms or Signs of Carotid Stenosis-related Brain Injury: IVUS Controlled Investigator Initiated Multcentric Multi-specialty Study

Loyola University Chicago Pipeline Products & Ongoing Clinical Trials Overview

Intravascular Stent – Product Status

Intravascular Stent – Product Description

MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview

Taurus Carotid Stent – Product Status

Taurus Carotid Stent – Product Description

Nesstent Ltd. Pipeline Products & Ongoing Clinical Trials Overview

NesStent’s Stent – Carotid Bifurcation – Product Status

NesStent’s Stent – Carotid Bifurcation – Product Description

Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview

Micro-Mesh Covered Carotid Stent – Product Status

Micro-Mesh Covered Carotid Stent – Product Description

Shanghai HeartCare Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

Carotid Artery Stent – Product Status

Carotid Artery Stent – Product Description

Shanghai HeartCare Medical Technology Co Ltd – Ongoing Clinical Trials Overview

Carotid Artery Stent – The Safety and Efficacy of Carotid Artery Stenting in Carotid Stenosis: A Prospective Multicenter, Non-inferiority Design, Randomized, Controlled Clinical Trial

SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview

Renal Stent System – Product Status

Renal Stent System – Product Description

Glossary

Figures

Carotid and Renal Artery Stents – Pipeline Products by Stage of Development

Carotid and Renal Artery Stents – Pipeline Products by Segment

Carotid and Renal Artery Stents – Pipeline Products by Territory

Carotid and Renal Artery Stents – Pipeline Products by Regulatory Path

Carotid and Renal Artery Stents – Pipeline Products by Estimated Approval Date

Carotid and Renal Artery Stents – Ongoing Clinical Trials

Frequently asked questions

Carotid and Renal Artery Stents Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Carotid and Renal Artery Stents Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Carotid and Renal Artery Stents reports
Medical Devices
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Medical Devices
New
Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…
$495 | July 2026
Medical Devices
New
AI-designed Materials: Market Trends and Innovations
$995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Carotid and Renal Artery Stents Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies in real time.

  • Access a live Carotid and Renal Artery Stents Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more